Revance Reports Third Quarter 2020 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Revance Therapeutics (RVNC) Misses Q3 EPS by 31c, Revenues Beat
November 9, 2020 5:00 PM ESTRevance Therapeutics (NASDAQ: RVNC) reported Q3 EPS of ($1.34), $0.31 worse than the analyst estimate of ($1.03).
The third quarter of 2020 marked a significant milestone in the companys history as Revance successfully transitioned to a fully integrated commercial enterprise. I am very pleased with the positive, early market feedback on our RHA® Collection of dermal fillers and HintMD fintech platform. We have assembled a portfolio of differentiated and unique assets for our aesthetics franchise and we believe we have the right... More
